Mediator and outcomes | Direct effect (£,) | Indirect effect (α#β)3 | Proportion of mediation, % | ||
---|---|---|---|---|---|
Estimate | P | Estimate | Sobel test statistic | ||
BMI | |||||
Serum Hs-CRP (mg/dl) | −0.020 | < 0.001 | − 0.007 | < 0.001 | 26.6% |
Serum Apolipoprotein (B) (mg/dL) | −0.382 | 0.124 | −0.083 | < 0.001 | 17.6% |
Fasting blood glucose (mg/dl) | −0.832 | < 0.001 | −0.235 | < 0.001 | 22.2% |
Plasma Insulin (uU/mL) | −0.014 | 0.019 | −0.0096 | 0.013 | 40.1% |
HOMA_IR | −0.021 | < 0.001 | −0.010 | 0.014 | 33.7% |
HOMA_B | −0.001 | 0.882 | −0.005 | 0.021 | 84.3% |
HbA1c (%) | −0.019 | < 0.001 | −0.078 | < 0.001 | 28.3% |
2-h blood glucose(mg/dL) | −2.235 | < 0.001 | − 0.198 | 0.0831 | 8.1% |
TyG index | −0.007 | 0.102 | −0.007 | < 0.001 | 51.3% |
WC | |||||
 Serum Hs-CRP (mg/dl) | −0.021 | < 0.001 | −0.058 | < 0.001 | 21.5% |
 Serum Apolipoprotein (B) (mg/dL) | −0.307 | 0.214 | −0.079 | 0.074 | 20.4% |
 Fasting blood glucose (mg/dl) | −0.853 | < 0.001 | −0.198 | < 0.001 | 18.8% |
 Plasma Insulin (uU/mL) | −0.014 | < 0.001 | −0.075 | 0.062 | 34.2% |
 HOMA_IR | −0.021 | < 0.001 | −0.008 | 0.067 | 28.3% |
 HOMA_B | −0.001 | 0.846 | −0.004 | 0.083 | 77.1% |
 HbA1c (%) | −0.020 | < 0.001 | −0.006 | < 0.001 | 23.1% |
 2-h blood glucose(mg/dL) | −2.196 | < 0.001 | − 0.204 | 0.092 | 8.5% |
 TyG index | −0.006 | 0.147 | −0.007 | < 0.001 | 52.1% |
apVAT | |||||
 Serum Hs-CRP (mg/dl) | 0.003 | 0.733 | −0.005 | 0.022 | 62.3% |
 Serum Apolipoprotein (B) (mg/dL) | 0.351 | 0.462 | −0.062 | 0.522 | 1.2% |
 Fasting blood glucose (mg/dl) | −0.471 | 0.273 | 0.163 | 0.026 | 25.3% |
 Plasma Insulin (uU/mL) | −0.006 | 0.561 | −0.005 | 0.488 | 44.5% |
 HOMA_IR | −0.009 | 0.455 | −0.005 | 0.509 | 37.2% |
 HOMA_B | 0.001 | 0.952 | −0.002 | 0.644 | 99.2% |
 HbA1c (%) | −0.020 | 0.082 | −0.005 | 0.017 | 21.1% |
 2-h blood glucose(mg/dL) | −1.162 | 0.244 | −0.410 | 0.154 | 26.0% |
 TyG index | −0.005 | 0.511 | −0.007 | 0.023 | 57.2 |